KR20220001553A - Composition for prevention and improvment of reflux esophagitis - Google Patents

Abstract

The present invention relates to a Cheongwi-tang composition for preventing or treating reflux esophagitis. More specifically, the present invention relates to food or a pharmaceutical composition which contains a hot water extract of medicinal herbs as an active component, wherein the medicinal herbs contain Cyperus rotundus, Atractylodes lancea, Citrus unshiu peel, Machilus thunbergii, Pinellia ternata, Poria cocos, forsythia fruits, Raphanus sativus seeds, Poncirus trifoliata fruits, Scutellaria baicalensis, and Coptis japonica. According to the present invention, the composition of the present invention can be easily taken, is harmless to the human body even if consumed for a long period of time, and has an effect of effectively preventing or treating reflux esophagitis or cholangitis.

Description

Cheongwi-tang composition for preventing or treating reflux esophagitis {Composition for prevention and improvment of reflux esophagitis}

The present invention relates to a cheongwi-tang composition for preventing or treating reflux esophagitis, and more particularly, reflux containing extracts of hyangbuja, changjang, dermis, squash, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon as active ingredients. It relates to a composition for preventing or treating esophagitis.

Gastroesophageal reflux disease (GRD) has been a common disease in Western countries such as Europe and the United States for a long time.

Heartburn is the most common symptom of reflux esophagitis. This usually refers to a burning pain, burning, bitterness, or discomfort that seems to rise from the tip of the cervix to the throat. These symptoms may radiate to the back or neck and may be accompanied by dysphagia, a feeling of difficulty swallowing food.

Acid reflux is also an important symptom, which refers to the return of sour, bitter, or digested food back into the mouth. Sometimes you may experience chest pain or a feeling of choking, and you may feel like you have a lump in your throat even when you are not eating. Repetitive pain or discomfort in the upper abdomen (concave chest) or a chronic cough may also be symptoms of reflux esophagitis.

Heartburn from reflux esophagitis can occur at any time of the day, but it is an important characteristic that it is usually worsened after eating or in a supine position. It is often confused with heartburn, but it is a symptom that appears more frequently in functional indigestion, stomach or duodenal ulcers, and tends to worsen symptoms in the upper abdomen (concave chest) before meals, that is, when the stomach is empty. Therefore, the symptoms and heartburn of reflux esophagitis are very similar, but the location and time of onset are slightly different.

The biggest problem with this disease is that once symptoms appear, they can often develop chronically and reduce quality of life. In other words, if the feeling of a foreign body in the throat persists, as well as chronic cough, bacteria act to break it down, and bad breath occurs, which interferes with group life. In addition, in the case of reflux esophagitis, if left untreated, it may develop into esophageal stricture or esophageal cancer, although rare. Therefore, it is of utmost importance to visit a hospital for an accurate diagnosis and treatment when symptoms are felt. In particular, in drug treatment that simply suppresses gastric acid, symptoms often recur when the drug is stopped or the dose is reduced, so fundamental treatment and dietary adjustment are necessary.

Various drugs that suppress gastric acid secretion are used for the treatment of reflux esophagitis, and the most commonly prescribed drugs are hydrogen pump inhibitors such as omeprazole or rabeprazole. This reduces the secretion of gastric acid by more than 90% and prevents the progression of esophageal lesions without causing symptoms even if reflux continues. Drugs that control the motility of the esophagus and lower esophageal sphincter are also used, and in some cases, the above drugs are used together. Drugs such as Zantac and Mylanta are used to suppress the secretion of gastric acid, or to cover the stomach acid with a membrane, which encloses the esophagus in advance to relieve inflammation. If non-steroidal anti-inflammatory drugs are used as inflammatory diseases, heartburn may occur due to the gastric acid secretion effect of the anti-inflammatory drugs. These include aspirin and ibuprofen.

If symptoms do not improve despite the above methods, surgery is recommended. There are some cases where surgery is required because of some complications, but these cases are very rare. Recently, a surgical method using a laparoscopy without opening the abdomen or chest has been developed.

However, the chemical synthetic drug treatment as described above may have an adverse effect on the human body during long-term treatment, and surgery has a disadvantage in that it places a great burden on the patient and the effect is not excellent.

On the other hand, biliary tract disease refers to a disease in which wastes and toxins generated from food that are not properly digested in the stomach accumulate on the gastrointestinal mucosa and outer walls and become hardened. Various digestive diseases such as intestinal epithelial metaplasia occur.

However, effective treatment methods for gallstone disease have not been limited so far.

Therefore, there is a need to develop a method for improving and preventing reflux esophagitis and biliary tract disease by using natural ingredients in addition to chemical synthetic drug treatment and surgical therapy.

KR 10-1808328 B1 KR 10-2082860 B1 KR 10-1789392 B1

Accordingly, it is an object of the present invention to provide a cheongwi-tang composition capable of inhibiting esophageal cell damage and inflammatory response caused by acid reflux and effectively preventing or treating reflux esophagitis or cholestasis.

In addition, by using an extract derived from a natural product as an active ingredient, there is no side effect, and it is to provide a Cheongwi-tang composition that can be consumed for a long time.

The Cheongwi-tang composition for the prevention or treatment of reflux esophagitis of the present invention for achieving the above object includes, as an active ingredient, a hot water extract of a medicinal agent, wherein the medicinal agent is Hyangbuja, Genesis, dermis, Hubak, Banha, Jeokbokryeong, Yeongyo, Nabokja. , and contains ginseng, gold and yellow lily, it is characterized in that it is a food or pharmaceutical composition.

The medicine is, with respect to 100 parts by weight of the hyangbuja, creation 25-40 parts by weight, dermis 25-40 parts by weight, husk 25-40 parts by weight, banha 25-40 parts by weight, Jeokbokryeong 25-40 parts by weight, Yeongyo 25- It is characterized in that it contains 40 parts by weight, 25-40 parts by weight of licorice root, 25-40 parts by weight of licorice, 20-30 parts by weight of gold and 20-30 parts by weight of yellow lily.

The medicine is characterized in that it further comprises 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose.

The medicinal material is characterized in that it further comprises at least one of 10-20 parts by weight of goryanggang, 10-20 parts by weight of sagebrush, 10-20 parts by weight of osuyu, and 10-20 parts by weight of blackberry fruit.

The Cheongwi-tang composition for preventing or treating reflux esophagitis according to the present invention can be easily taken, is harmless to the human body even when consumed for a long period of time, and has the effect of effectively preventing or treating reflux esophagitis or biliary tract disease.

Hereinafter, the present invention will be described in detail.

The greatest feature of the present invention is that it effectively prevents or treats gastroesophageal reflux disease or biliary tract disease only with extracts of natural medicinal substances. That is, the Cheongwi-tang composition according to the present invention refers to a composition having a preventive or therapeutic effect on reflux esophagitis or biliary tract disease, and the composition may be a food or pharmaceutical composition. Specifically, the Cheongwi-tang composition of the present invention may be provided in the form of a food such as a beverage or liquid tea, or as a pharmaceutical composition, may be provided as a liquid or capsule for oral administration. In addition, it may be provided in various known forms such as powder, pills, and the like.

In addition, the composition according to the present invention may consist only of extracts of medicinal substances, and various types of additives known for formulation may be added. However, even if various additives are added, the medicinal extract is used within the range of 10% by weight or more, that is, 10 to 100% by weight based on 100% by weight of the total composition.

For this purpose, the Cheongwi-tang composition of the present invention includes a hot water extract of medicinal herbs as an active ingredient, wherein the medicinal materials include hyangbuja, chrysanthemum, dermis, hubak, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon. do.

Briefly looking at the above medicinal materials, the Hyangbuja is a medicinal herb obtained by drying the rhizome of Hyangbuja, a perennial plant belonging to the family Sapaceae, and it is known that it treats nervous gastrointestinal diseases and indigestion caused by chronic stress.

The above creation is the dried root fruit of sapju, which strengthens the stomach and prevents obesity, treats dead skin tissue, jaundice, and convulsions, stops sweating, removes heat, and digests food. .

The dermis is dried tangerine (Citrus unshiu Markovich) or the mature pericarp of a closely related plant of the rutaceae family, which releases agglomeration and strengthens the function of the spleen to cause stomach upset, belching, vomiting, nausea, indigestion, flatulence It treats the symptoms of drowsiness and loose stools. In addition, seawater, removes phlegm and acts as a diuretic. It has been reported that essential oil components have digestive stimulation, digestion promotion, expectorant, anti-ulcer, anti-gastric secretion, strong heart, blood pressure increase, anti-allergy, biliary secretion promotion, uterine smooth muscle suppression, and antibacterial action.

The sagebrush is a dried stem bark of Magnolia ovobata Thunberg, Magnolia officinalis Rehder et Wilson, or coniferous squash, Magnolia officinalis Rehder et Wilson var. biloba Rehder et Wilson belonging to the Magnolia family. The active ingredients are lignans and essential oils. The sagebrush has excellent anti-inflammatory and antibacterial effects, and has the effect of treating cough, treating body aches, and knocking down clogged turbid walls. In addition, it relieves indigestion, is often used in the treatment of gastritis and enteritis, and plays a role in facilitating bowel movements.

The above-mentioned antibacterial (Pinellia ternata Breitenbach) is a dried tuber from which the cork layer has been removed. It is used for sputum, seawater, and asthma as it treats dampness. , It is used for boils on the back, mastitis, and vomiting during pregnancy. Expectorant, antitussive, vomiting sedation, silicosis prevention, anticancer action, etc. have been reported as the pharmacological actions of the antihas.

The jeokbokryeong is a parasitic bacterium on a pine tree, and after cutting a pine tree, sprouts do not come out again, but the root does not die and the sap flows down, so bokryeong occurs. It has a gentle diuretic effect, so it is effective when the digestive system is weak and there is edema all over the body. It is also effective in nephritis, cystitis, and urethritis. In addition, since it has an expectorant action, it is being combined with an expectorant antitussive drug to treat chronic bronchitis and bronchiectasis, which are symptoms that produce a lot of phlegm and have difficulty breathing. In addition, it has a gastric action, so it is used for chronic gastroenteritis that causes excessive water retention in the stomach to cause bloating and vomiting. is used as

The Yeongyo is the dried fruit of Forsythia viridissima Lindley or Forsythia suspensa Vahl of the ash family. It has the effect of dissolving clumping or clumping. Therefore, it can be used for fever, lymphadenitis, sore throat, etc., or to relieve high fever and confusion by lowering heat in the early stages of fever. Antibacterial action, anti-inflammatory action, blood pressure lowering, hemostatic action, liver treatment action, antipyretic action, anti-emetic action, and diuretic action have been reported as pharmacological actions. saponin) and oleanolic acid.

The larvae are medicinal products made using the seeds of cruciferous radish (Raphanus sativus L.) or animals and plants, and have the effect of passing the qi and lowering the body. It lowers qi and removes phlegm, and is effective for seawater, asthma, and constipation. It is effective in treating anorexia and stopping old phlegm and old cough. As pharmacological action, inhibitory action against staphylococcus, etc., skin fungus suppression action, blood pressure lowering action, anti-inflammatory action, etc. have been reported.

The branch is the dried unripe fruit of Poncirus trifoliata Rafin, which disperses the molybdenum, aids digestion, and removes phlegm. In pharmacological experiments, uterine contraction action, gastrointestinal peristalsis enhancing action, blood pressure increase action, cardiac action, and diuretic action were found. It is used for gastrointestinal disorders, digestive disorders, abdominal distension, constipation, dysentery, uterine fibroids, gastric pitting, prolapse, gastric dilatation, and gastritis.

The gold is a medicinal herb that has dried its roots, and contains Baicalein, Baicalin, Wogonin, Wogonoside, etc. to relieve excessive heat accumulated in the body, It has anti-inflammatory action.

The yellow lotus root is collected and dried, and has effects such as dryness, sedation, anti-inflammatory and antibacterial properties. It is prescribed for the treatment of sore throat (咽喉腫痛), hematemesis, nosebleeds, bleeding, and burns. It lowers heat, removes wet sand, and cleanly removes and detoxifies fire. In pharmacological experiments, it was found that berberine, the main ingredient, exhibits antibacterial action, sedative and antispasmodic action against intestinal bacteria, anti-arteriosclerosis action, anti-inflammatory action, biliary tract action, and pancreatic secretion promoting action.

The present invention suppresses esophageal cell damage and inflammatory response through the interaction of these drugs, and effectively prevents or treats reflux esophagitis or biliary tract disease.

In the present invention, the extract refers to a hot-water extract of medicinal substances, and the hot-water extract can be prepared according to a conventionally published conventional method, illustratively by adding 5 to 30 times by weight of water to the medicinal material, and 80 It can be prepared by heating to ˜100° C. for 5 to 40 hours and filtering. In addition, it is natural that the extract can be filtered or concentrated or dried to remove water as a solvent, if necessary.

In addition, the mixing ratio of the drug is 25-40 parts by weight of creation, 25-40 parts by weight of dermis, 25-40 parts by weight of squash, 25-40 parts by weight of Banha, 25-40 parts by weight of Jeokbokryeong, 25-40 parts by weight of Yeongyo with respect to 100 parts by weight of Hyangbuja It is preferable to include ~40 parts by weight, 25-40 parts by weight of licorice root, 25-40 parts by weight of licorice, 20-30 parts by weight of gold and 20-30 parts by weight of yellow lily, which is a component of each drug, pharmacological action, anti-inflammatory effect, etc. (Hereinafter, 'part by weight' is based on 100 parts by weight of the hyangbuja.)

On the other hand, the medicine may further include 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose. The dandelion flower refers to the dried product of the dandelion flower, and the evening primrose refers to the dried product of the evening primrose, and it more effectively inhibits damage and inflammation of esophageal cells with strong antibacterial and anti-inflammatory action.

In addition, the medicinal material further includes at least one of 10-20 parts by weight of goryanggang, 10-20 parts by weight of sagebrush root, 10-20 parts by weight of osuyu, and 10-20 parts by weight of sagebrush, preferably all four types. can do. These drugs are not only effective for reflux esophagitis, but also improve cholestasis more effectively.

The goryanggang (Alpinia officinarum) is a perennial herb belonging to the ginger family, and the rhizomes are harvested in autumn and dried, used for chronic gastritis, abdominal pain, vomiting, etc. It effectively prevents or treats reflux esophagitis or biliary tract disease by thrombotic action.

The root of the blueberry contains Chrysophanol and Emodin, which are derivatives of traquinone (Anthraquinon), and is used for indigestion and the like.

The Osuyu is a dried fruit of Osuyu belonging to the Unhyangwa family, and has excellent antithrombotic and anti-inflammatory properties.

The fruit of Xanthium strumarium var. japonicum HARA has been reported to have effects such as analgesia, mountain wind, dampness, small swelling, and the like, and in the present invention, the drug is esophageal and more effectively inhibit the inflammatory response.

The composition of the present invention as described above, by interaction between each drug, inhibits damage and inflammatory reaction of esophageal cells, can effectively prevent or treat reflux esophagitis or cholangitis, as well as extracts derived from natural products as active ingredients By doing so, there is no side effect, and long-term intake is possible.

A preferred dosage or intake amount of the composition according to the present invention may be appropriately selected by those skilled in the art, for example, the active ingredient according to the present invention may be administered or ingested once a day at 0.0001 to 100 mg/kg per day. and may be administered or ingested in several divided doses, but is not necessarily limited thereto.

Hereinafter, the present invention will be described in detail by way of Examples.

(Example 1)

For 120g of Hyangbuja, 10kg of water was extracted from medicinal herbs of 40g of Hyangbuja, 40g of ginseng 40g, 40g of squash, 40g of Banha, 40g of Jeokbokryeong, 40g of Yeongyo, 40g of Nabokja, 40g of Jisil, 28g of golden lily and 28g of Hwangryeon at 80~100℃ for 20 hours, filtered.

(Example 2)

It was carried out in the same manner as in Example 1, except that 15 g of dandelion flowers and 15 g of evening primrose were further used as medicinal materials.

(Example 3)

It was carried out in the same manner as in Example 2, except that 15 g of goryanggang, 15 g of turmeric root, 15 g of osuyu and 15 g of blackberry fruit were further used as medicinal materials.

(Test Example 1)

Hydrochloric acid is the main component of gastric acid, and reflux esophagitis is caused by an inflammatory reaction caused by damage to esophageal cells caused by acid reflux. Therefore, an in vitro test was conducted on whether the extract inhibits esophageal cell damage caused by hydrochloric acid. At this time, each extract was concentrated under reduced pressure and freeze-dried.

First, human esophageal cells Het-1a were purchased from ATCC (American Type Culture Collection) and cultured in a 37° C., 5% CO ₂ incubator using BEGM™ medium (Lonza). The cultured human esophageal cells, Het-1a cells, were dispensed in a 96-well plate at 2×10 ⁴ cells/well and cultured for 24 hours, and then 10 μg/mL of each extract and hydrochloric acid were added to a final concentration of 10 mM, respectively. processed to be this. After 6 hours of the hydrochloric acid treatment, MTT solution (SIGMA, M5655) was added and incubated for an additional hour, then the generated formazan was dissolved by adding dimethyl sulfoxide (DMSO), and absorbance at 540 nm was obtained. By measuring the cell viability was measured.

On the other hand, the control group was tested in the same manner as above except that the same amount of phosphate buffered saline (PBS) was treated instead of the extract.

The results are shown in Table 1 below.

Test Example 1 Results division Cell viability (%) Example 1 90.1 Example 2 91.7 Example 3 92.5 control 75.8

As can be seen in Table 1, in the control group, about 25% of apoptosis was achieved, whereas in Examples 1 to 3 of the present invention, it was confirmed that the death of esophageal cells was significantly reduced.

(Test Example 2)

It has been reported that IL-6, an inflammatory cytokine, is an important factor in the inflammatory response of esophageal cells by acid. Therefore, an in vitro test was performed on whether each of the extracts inhibits the esophageal cell inflammatory response by inhibiting IL-6 increased by acid. At this time, each extract was concentrated under reduced pressure and freeze-dried.

Human esophageal cells, Het-1a cells, were aliquoted in a 96-well plate at 2×10 ⁴ cells/well and cultured for 24 hours, and then each extract was treated to a final concentration of 10 μg/ml. After 1 hour of treatment with the extract, the medium was removed and the medium was replaced with a medium in which the pH of the medium was lowered from 7.2 to 4.5 by the addition of hydrochloric acid. After 1 hour of pH 4.5 medium treatment, the medium was removed again and replaced with a normal medium of pH 7.2, and then the cells were cultured in a _{37° C., 5% CO 2 incubator for 6 hours.} After 6 hours of incubation, the cells were washed 3 times with PBS (phosphate buffered saline), and then treated with trizol reagent (sigma) in each well to isolate total RNA. After quantification, the same amount of isolated total RNA was taken and cDNA was synthesized using the High Capacity cDNA Kit (thermofisher), and then qPCR was performed using SYBR Premix Ex Taq™ (Takara) and IL-6 primer (Hs00174131_m1, thermofisher). Thus, the relative expression level of IL-6 was measured.

On the other hand, the control group was tested in the same manner as above except that the pH4.5 medium was not treated and the extract was not treated, and the positive control group was tested in the same way as above except that the extract was not treated. did

The results are shown in Table 2 below.

Test Example 2 Results division Example 1 Example 2 Example 3 positive control control IL-6 expression (Fold) 3.74 3.51 3.15 5.21 One

As can be seen in Table 2, in the case of the positive control of the present invention, the expression of IL-6 was greatly increased by hydrochloric acid, whereas in Examples 1 to 3, it was confirmed that the expression of IL-6 by hydrochloric acid was reduced. . This indicates that when gastric acid reflux stimulates esophageal cells, Examples 1 to 3 of the present invention can suppress the inflammatory response caused by gastric acid at the gene level.

(Test Example 3)

40 adult males and 40 females with gastroesophageal reflux symptoms were divided into four groups of 10 males and females each as a test group, and 100g of each Example or Comparative Example 1 was administered 3 times a day for each group. They were given at intervals of 8 hours, and the degree of improvement of reflux esophagitis was evaluated on the 10th, 20th, and 30th days after taking, and the results (average values of 20 patients) are shown in Table 3 below. In Comparative Example 1, 1 kg of water was added to 100 g of Hyangbuja, extracted at 80-100° C. for 20 hours, and filtered.

Test Example 3 Results division after 10 days after 20 days 30 days later Example 1 2.7 3.5 4.8 Example 2 2.8 3.7 5.0 Example 3 3.0 4.2 5.3 Comparative Example 1 2.1 2.5 2.7 <Evaluation criteria>
6: 100% improved, 5: 80% improved,
4: 50% improvement, 3: 20% improvement,
2: No change, 1: Worse

As can be seen in Table 3 above, it was confirmed that the composition of the present invention clearly improved the effect of improving reflux esophagitis.

(Test Example 4)

20 adult males and 20 females with symptoms of cholestasis were divided into four groups of 5 males and females each, and 100g of each Example or Comparative Example 1 was administered 3 times a day for each group. They were given at intervals of 8 hours, and the degree of improvement of cholestasis was evaluated on the 10th, 20th, and 30th days after taking, and the results (average value of 10 patients) are shown in Table 4 below. In Comparative Example 1, 1 kg of water was added to 100 g of Hyangbuja, extracted at 80-100° C. for 20 hours, and filtered.

Test Example 4 Results division after 10 days after 20 days 30 days later Example 1 2.1 2.9 4.1 Example 2 2.4 3.4 4.8 Example 3 2.7 4.4 5.9 Comparative Example 1 2.0 2.2 2.5 <Evaluation criteria>
6: 100% improved, 5: 80% improved,
4: 50% improvement, 3: 20% improvement,
2: No change, 1: Worse

As can be seen in Table 3 above, it was confirmed that the composition of the present invention clearly obtained an excellent effect of improving gallbladder disease.

Although the present invention has been described in detail using preferred embodiments, the scope of the present invention is not limited to specific embodiments, and should be construed by the appended claims. In addition, those skilled in the art will understand that many modifications and variations are possible without departing from the scope of the present invention.

Claims (4)

Contains hot water extract of medicinal herbs as an active ingredient,
The medicinal materials include hyangbuja, chrysanthemum, ginseng, hubak, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon,
Cheongwi-tang composition for preventing or treating reflux esophagitis, characterized in that it is a food or pharmaceutical composition.
According to claim 1,
The drug is
With respect to 100 parts by weight of the hyangbuja, creation 25-40 parts by weight, dermis 25-40 parts by weight, husk 25-40 parts by weight, banha 25-40 parts by weight, jeokbokryeong 25-40 parts by weight, annual bridge 25-40 parts by weight, Cheongwi-tang composition for preventing or treating reflux esophagitis, characterized in that it contains 25-40 parts by weight of Nabokja, 25-40 parts by weight of licorice, 20-30 parts by weight of gold and 20-30 parts by weight of hwangryeon.
3. The method of claim 2,
The drug is
Cheongwi-tang composition for preventing or treating reflux esophagitis, characterized in that it further comprises 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose.
4. The method of claim 2 or 3,
The drug is
Blue for the prevention or treatment of reflux esophagitis, characterized in that it further comprises at least one of 10-20 parts by weight of goryanggang, 10-20 parts by weight of sagebrush root, 10-20 parts by weight of osuyu, and 10-20 parts by weight of sagebrush. stomach composition.